Showing results (1801-1810 of 1,853) with videos related to
Sort By:
Pageof 186
Journal of Managed Care & Specialty Pharmacy|September 30, 2024
Best practices and rationale for expanding Medicaid access to continuous glucose monitoringCynthia A King, Amber N LillyJournal of Managed Care & Specialty Pharmacy|September 25, 2024
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United StatesXiaodan Mai, Aaron B Mendelsohn, James Marshall, et al.Journal of Managed Care & Specialty Pharmacy|August 1, 2024
Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysisRaymond C Chang, Joanna Huang, James Hurst, et al.Journal of Managed Care & Specialty Pharmacy|September 30, 2024
Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measureMarissa Morris-Murray, Marie FrazzittaJournal of Managed Care & Specialty Pharmacy|September 30, 2024
Advances in diabetes technology within the digital diabetes ecosystemHalis Kaan Akturk, Anila BindalJournal of Managed Care & Specialty Pharmacy|September 25, 2024
A retrospective claims data analysis of health care utilization and cost among patients receiving multi-injection intraarticular hyaluronic acidMathew Nicholls, Kaiwen Guo, Yen-Hua Chen, et al.Journal of Managed Care & Specialty Pharmacy|September 27, 2024
Evaluating the burden of illness of metabolic dysfunction-associated steatohepatitis in a large managed care population: The ETHEREAL StudyMichael Charlton, Ivy Tonnu-Mihara, Chia-Chen Teng, et al.Journal of Managed Care & Specialty Pharmacy|August 1, 2024
Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi studyJennifer S GraffJournal of Managed Care & Specialty Pharmacy|August 1, 2024
The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia BJyotirmoy Sarker, Jeffrey A Tice, David M Rind, et al.Journal of Managed Care & Specialty Pharmacy|August 1, 2024
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights ProgramTerry Richardson, Brian P Vickery, Ruchi Gupta, et al.Pageof 186